Complete Genomics, the Mountain View, CA-based company with a new model for inexpensive gene sequencing, has filed a prospectus with the Securities and Exchange Commission to go public. The company hopes to raise as much as $86 million through an IPO that would be underwritten by UBS, Baird, Jefferies & Co., and Cowen & Co. Complete Genomics already has a couple of well-known investors in public biotech companies—OrbiMed Advisors and Essex Woodland Health Ventures—among its top stockholders, as well as some traditional venture backers who hope to cash out—San Diego-based Enterprise Partners Venture Capital, Kirkland, WA-based OVP Venture Partners, and Palo Alto, CA-based Prospect Venture Partners.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
